Prometheus reportedly drew a competing AbbVie bid, initial partner interest from 16 pharmas before inking $10.8B Merck buyout

Andrew Dunn

Senior Biopharma Correspondent

In the week after this year’s JP Morgan Healthcare Conference, Prometheus Biosciences CEO Mark McKenna got a phone call that would change the biotech’s future …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Prometheus reportedly drew a competing AbbVie bid, initial partner interest from 16 pharmas before inking $10.8B Merck buyout

Andrew Dunn

Senior Biopharma Correspondent

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

In surprise, study suggests Covid mRNA vaccines may boost cancer immunotherapy efficacy

Pfizer tees up Phase 3 test in weight management — but in an unexpected area

Ex-Kite leaders step in at Kyverna as CEO exits after landing year's second-biggest IPO

BioNTech rolls out Phase 2 lung cancer data as VEGF bispecifics take center stage

Immatics loses Bristol Myers' support on Phase 1 bispecific T cell engager

Breaking down silos with a new quantitative approach to drug development

Prometheus re­port­ed­ly drew a com­pet­ing Ab­b­Vie bid, ini­tial part­ner in­ter­est from 16 phar­mas be­fore ink­ing $10.8B Mer­ck buy­out

Senior Biopharma Correspondent

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Prometheus reportedly drew a competing AbbVie bid, initial partner interest from 16 pharmas before inking $10.8B Merck buyout